lonazolac

Lonazolac is a nonsteroidal anti-inflammatory drug (NSAID) of the phenylpyrazole class, structurally related to acetic acid derivatives. It acts primarily by inhibiting cyclooxygenase (COX) enzymes, specifically both COX‑1 and COX‑2, leading to reduced synthesis of prostaglandins involved in inflammation, pain signaling, and fever. In addition to its anti-inflammatory and analgesic effects, lonazolac has been shown to modulate immune responses by affecting mononuclear cell activity and reducing histamine release from basophils. It also inhibits leukotriene generation in polymorphonuclear leukocytes and affects platelet activating factor metabolism. Clinically, it is indicated for the treatment of painful inflammatory rheumatic diseases of the joints and spine (such as osteoarthritis and spondylosis), soft tissue rheumatism, as well as post-traumatic or postoperative pain and swelling[1][5][6][7].

Brand names

ArgunIrriten

Other names

LonazolacoLonazolacumlonazolac calciumlonazolac calcium salt3-(4-chlorophenyl)-1-phenylpyrazole-4-acetic acid